What is MBX Biosciences, Inc. Common Stock?
, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.78B.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.